News Sentiment

IXHL sentiment intelligence

Incannex Healthcare Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 71 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.39 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 71

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend inactive

-14.6% over one week, -11.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -14.6% Price reacting lower
Trend fit Trend inactive -11.5% over four weeks
Fair value -92.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 44
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 71
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
GlobeNewswire 6
Investing.com 5
Meyka 4
StockStory 3
Market source 3
MarketBeat 3
Barron's 3

Event Lens

What the news is about

Classified themes
Market update 49
Earnings 11
Balance sheet 4
Capital return 3
Analyst action 3
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 71
Stock Titan Direct company coverage

[8-K] Incannex Healthcare Inc. Reports Material Event

Incannex Healthcare Inc. (IXHL) announced it has secured over A$11.1 million in non-dilutive R&D funding, including A$6.0 million already received and an additional A$5.1 million expected in 2026, through the Australian Government’s Research and Development Tax Incentive Program.

Tone
Positive 74/100
Event
Market update
Published
10 Jun 2026 17:39
Source
Stock Titan
Investing.com UK Direct company coverage

Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com

Incannex Healthcare Inc. (NASDAQ:IXHL) has received A$6,039,162.43 from the Australian Government’s Research and Development Tax Incentive Program and anticipates an additional A$5.1 million in 2026, totaling over A$11.1 million in non-dilutive capital. This funding will support

Tone
Positive 74/100
Event
Market update
Published
10 Jun 2026 13:22
Source
Investing.com UK
Bitget Direct company coverage

Biopharmaceutical company Incannex Healthcare Ltd (IXHL) receives inaugural coverage report from Alliance Global Partners.

Alliance Global Partners has initiated coverage on Incannex Healthcare Ltd (IXHL) with a "Buy" rating and a target price of $18. This positive outlook from analysts suggests a strong belief in the biopharmaceutical company's future prospects. The report highlights Incannex Health

Tone
Positive 71/100
Event
Analyst action
Published
08 Jun 2026 17:39
Source
Bitget
Stock Titan Direct company coverage

Incannex (IXHL) launches DReAMzz dose-optimization study of IHL-42X for sleep apnea

Incannex Healthcare Inc. has officially commenced its DReAMzz clinical study for IHL-42X, a drug candidate for obstructive sleep apnea (OSA). This crossover dose-optimization trial aims to refine the dosing profile and inform the design of a planned Phase III development program,

Tone
Neutral 50/100
Event
Market update
Published
17 May 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Incannex Healthcare (NASDAQ: IXHL) grows cash to $74.5M amid $16.8M loss

Incannex Healthcare Inc. (NASDAQ: IXHL) reported a net loss of $16.8 million for the nine months ended March 31, 2026, though its cash and cash equivalents significantly increased to $74.5 million, up from $15.0 million in June 2025, primarily due to equity financings. The compan

Tone
Neutral 50/100
Event
Balance sheet
Published
16 May 2026 06:39
Source
Stock Titan
Quiver Quantitative Direct company coverage

Incannex Healthcare Inc. Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Treatment

Incannex Healthcare Inc. has initiated its DReAMzz clinical study for IHL-42X, a treatment for obstructive sleep apnea (OSA). This milestone advances the drug towards late-stage development following positive Phase II results and an FDA Fast Track designation. The study aims to o

Tone
Positive 82/100
Event
Earnings
Published
14 May 2026 14:40
Source
Quiver Quantitative
Stock Titan Direct company coverage

New oral sleep apnea drug IHL-42X wins global MedTech prize

Incannex Healthcare (Nasdaq: IXHL) has won the MedTech Breakthrough “Best New Technology Solution for Drug Development” award for its lead candidate, IHL-42X, an oral combination therapy for obstructive sleep apnea (OSA). Phase 2 data for IHL-42X showed statistically significant

Tone
Negative 30/100
Event
Market update
Published
13 May 2026 05:09
Source
Stock Titan